Cytopheresis cartridges and use thereof
AssigneeSeaStar Medical, Inc.
InventorsH. David Humes, Deborah A. Buffington, Christopher J. Pino
Life of this patent
Estimating the term…
Abstract
The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions within a subject and to related methods. More particularly, the invention relates to a cytopheretic cartridge that includes a housing and, disposed within the housing, a solid support capable of sequestering activated leukocytes and/or platelets.
Claims32
A cartridge for treating activated leukocytes, activated platelets, or both activated leukocytes and activated platelets, comprising:
- (a) a rigid housing defining an inner volume (IV), a fluid inlet port and a fluid outlet port, wherein the inner volume is in fluid flow communication with the fluid inlet port and the fluid outlet port;
- and
- (b) a solid support disposed within the housing and defining a fluid contacting surface with a surface area (SA) capable of sequestering an activated leukocyte and/or an activated platelet if present in a body fluid entering the housing via the fluid inlet port, wherein the SA/IV ratio is greater than 150 cm−1 and the solid support is disposed within the housing at a packing density in the range from 20% to 65%.
3-9. (canceled)
(canceled)
14-15. (canceled)
17-22. (canceled)
(canceled)
26-30. (canceled)
(canceled)
A method for processing an activated leukocyte, an activated platelet, or both an activated leukocyte and an activated platelet contained within a body fluid, the method comprising:
- (a) providing a cartridge comprising
- (i) a rigid housing defining an inner volume (IV), a fluid inlet port and a fluid outlet port, wherein the inner volume is in fluid flow communication with the fluid inlet port and the fluid outlet port;
- and
- (ii) a solid support disposed within the housing and defining a fluid contacting surface with a surface area (SA) capable of sequestering an activated leukocyte and/or an activated platelet if present in a body fluid entering the housing via the fluid inlet port, wherein the SA/IV ratio is greater than 80 cm−1;
- and
- (b) introducing a body fluid from a subject into the housing via the fluid inlet port under conditions that permit sequestration of an activated leukocyte and/or an activated platelet on the fluid contacting surface of the solid support.
(canceled)
A method for treating a subject having or at risk of developing an inflammatory condition, the method comprising:
- (a) providing a cartridge comprising
- (i) a rigid housing defining an inner volume (IV), a fluid inlet port and a fluid outlet port, wherein the inner volume is in fluid flow communication with the fluid inlet port and the fluid outlet port;
- and
- (ii) a solid support disposed within the housing and defining a fluid contacting surface with a surface area (SA) capable of sequestering an activated leukocyte, if present in a body fluid entering the housing via the fluid inlet port, wherein the SA/IV ratio is greater than 80 cm−1;
- and
- (b) introducing a body fluid from a subject into the housing via the fluid inlet port under conditions that permit sequestration of an activated leukocyte and/or an activated platelet on the fluid contacting surface of the solid support.
42-46. (canceled)
48-52. (canceled)
54-55. (canceled)
57-111. (canceled)
Dependencies are inferred from the claim text.